No Data
No Data
New Analyst Forecast: $RARE Given $115.0 Price Target
Piper Sandler Initiates Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Announces Target Price $115
Express News | Piper Sandler Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $115
Ultragenyx Pharmaceutical (RARE) Gets a Buy From Piper Sandler
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Revenues Are Not Doing Enough For Some Investors
2024 Wilson Disease Pipeline Market Analysis Report Featuring Alexion Pharmaceuticals, Inc., Vivet Therapeutics SAS, Ultragenyx Pharmaceutical and Nobelpharma